1例SMARCA4胚系变异卵巢高钙血症型小细胞癌的综合治疗和遗传咨询

doi:10.19401/j.cnki.1007-3639.2022.11.010

中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (11): 1115-1120.doi: 10.19401/j.cnki.1007-3639.2022.11.010

1例SMARCA4胚系变异卵巢高钙血症型小细胞癌的综合治疗和遗传咨询

郜意¹^,²(), 康茗贻¹^,², 王辉³, 胥婧¹^,², 石月¹, 陶祥⁴, 马凤华⁵, 谭灏文⁶, 康玉¹^,²(), 徐丛剑¹^,²^,⁷

1.复旦大学附属妇产科医院妇科，上海 200011
2.上海市女性生殖内分泌相关疾病重点实验室，上海 200011
3.复旦大学附属妇产科医院护理部，上海 200011
4.复旦大学附属妇产科医院病理科，上海 200011
5.复旦大学附属妇产科医院放射科，上海 200011
6.江西合因教育科技有限公司，江西赣州 342604
7.复旦大学上海医学院妇产科学系，上海，200032

收稿日期:2022-06-08 修回日期:2022-11-15 出版日期:2022-11-30 发布日期:2022-12-14
通信作者: 康玉
作者简介:郜意（ORCID: 0000-0003-3634-8087），博士在读。
基金资助:
上海申康医院发展中心临床科技创新项目(SHDC12020108);上海市老龄化和妇儿健康研究专项(2020YJZX0202)

Comprehensive therapy and genetic counseling for one patient with SMARCA4 germline-mutated small cell carcinoma, the ovary of hypercalcemic type

GAO Yi¹^,²(), KANG Mingyi¹^,², WANG Hui³, XU Jing¹^,², SHI Yue¹, TAO Xiang⁴, MA Fenghua⁵, TAN Haowen⁶, KANG Yu¹^,²(), XU Congjian¹^,²^,⁷

1. Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China
2. Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China
3. Department of Nursing, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China
4. Department of Pathology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China
5. Department of Radiology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China
6. Jiangxi Heyin Education Technology Co. Ltd., Ganzhou 342604, Jiangxi Province, China
7. Department of Obstetrics and Gynecology of Shanghai Medical School, Fudan University, Shanghai 200032, China

Received:2022-06-08 Revised:2022-11-15 Published:2022-11-30 Online:2022-12-14
Contact: KANG Yu

摘要/Abstract

关键词: 卵巢高钙血症型小细胞癌, SMARCA4, 综合治疗, 遗传咨询

Key words: Small cell carcinoma of the ovary, hypercalcemic type, SMARCA4, Comprehensive therapy, Genetic counseling

中图分类号:

R737.31

郜意, 康茗贻, 王辉, 胥婧, 石月, 陶祥, 马凤华, 谭灏文, 康玉, 徐丛剑. 1例SMARCA4胚系变异卵巢高钙血症型小细胞癌的综合治疗和遗传咨询[J]. 中国癌症杂志, 2022, 32(11): 1115-1120.

GAO Yi, KANG Mingyi, WANG Hui, XU Jing, SHI Yue, TAO Xiang, MA Fenghua, TAN Haowen, KANG Yu, XU Congjian. Comprehensive therapy and genetic counseling for one patient with SMARCA4 germline-mutated small cell carcinoma, the ovary of hypercalcemic type[J]. China Oncology, 2022, 32(11): 1115-1120.

图/表 4

参考文献 21

[1]	PODWIKA S E, JENKINS T M, KHOKHAR J K, et al. Optimal age for genetic cancer predisposition testing in hereditary SMARCA4 ovarian cancer families: how young is too young?[J]. Gynecol Oncol Rep, 2020, 32: 100569.
[2]	LEE E K, ESSELEN K M, KOLIN D L, et al. Combined CDK4/6 and PD-1 inhibition in refractory SMARCA4-deficient small-cell carcinoma of the ovary, hypercalcemic type[J]. JCO Precis Oncol, 2020, 4: 736-742.
[3]	CONNOR Y D, MIAO D A, LIN D I, et al. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: clinical features of a single family and comparison of large cohorts[J]. Gynecol Oncol, 2020, 157(1): 106-114. doi: 10.1016/j.ygyno.2019.10.031
[4]	HUGHES I A, HOUK C, AHMED S F, et al. Consensus statement on management of intersex disorders[J]. J Pediatr Urol, 2006, 2(3): 148-162. doi: 10.1016/j.jpurol.2006.03.004 pmid: 18947601
[5]	FOULKES W D, KAMIHARA J, EVANS D G R, et al. Cancer surveillance in gorlin syndrome and rhabdoid tumor predisposition syndrome[J]. Clin Cancer Res, 2017, 23(12): e62-e67. doi: 10.1158/1078-0432.CCR-17-0595
[6]	PEJOVIC T, MCCLUGGAGE W G, KRIEG A J, et al. The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type[J]. Gynecol Oncol Rep, 2019, 28: 47-49.
[7]	YOUNG R H, OLIVA E, SCULLY R E. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases[J]. Am J Surg Pathol, 1994, 18(11): 1102-1116. pmid: 7943531
[8]	CALLEGARO-FILHO D, GERSHENSON D M, NICK A M, et al. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): a review of 47 cases[J]. Gynecol Oncol, 2016, 140(1): 53-57. doi: 10.1016/j.ygyno.2015.11.004
[9]	WITKOWSKI L, GOUDIE C, RAMOS P, et al. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type[J]. Gynecol Oncol, 2016, 141(3): 454-460. doi: S0090-8258(16)30071-3 pmid: 26975901
[10]	JAMY O, YAGHMOUR G, HARE F, et al. Population-based analysis of the clinical features of primary small cell carcinoma of the ovary[J]. Anticancer Res, 2015, 35(5): 3091-3095. pmid: 25964600
[11]	ESTEL R, HACKETHAL A, KALDER M, et al. Small cell carcinoma of the ovary of the hypercalcaemic type: an analysis of clinical and prognostic aspects of a rare disease on the basis of cases published in the literature[J]. Arch Gynecol Obstet, 2011, 284(5): 1277-1282. doi: 10.1007/s00404-011-1846-5 pmid: 21298438
[12]	RAY-COQUARD I, MORICE P, LORUSSO D, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv1-iv18. doi: 10.1093/annonc/mdy001
[13]	WANG Y M, CHEN S Y, KARNEZIS A N, et al. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type[J]. J Pathol, 2017, 242(3): 371-383. doi: 10.1002/path.4912
[14]	WANG Y M, CHEN S Y, COLBORNE S, et al. Histone deacetylase inhibitors synergize with catalytic inhibitors of EZH2 to exhibit antitumor activity in small cell carcinoma of the ovary, hypercalcemic type[J]. Mol Cancer Ther, 2018, 17(12): 2767-2779. doi: 10.1158/1535-7163.MCT-18-0348 pmid: 30232145
[15]	SOLDI R, GHOSH HALDER T, WESTON A, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer[J]. PLoS One, 2020, 15(7): e0235705. doi: 10.1371/journal.pone.0235705
[16]	LANG J D, HENDRICKS W P D, ORLANDO K A, et al. Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multikinase inhibition[J]. Clin Cancer Res, 2018, 24(8): 1932-1943. doi: 10.1158/1078-0432.CCR-17-1928 pmid: 29440177
[17]	XUE Y B, MEEHAN B, MACDONALD E, et al. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary[J]. Nat Commun, 2019, 10(1): 558. doi: 10.1038/s41467-018-06958-9
[18]	JELINIC P, RICCA J, VAN OUDENHOVE E, et al. Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade[J]. J Natl Cancer Inst, 2018, 110(7): 787-790. doi: 10.1093/jnci/djx277 pmid: 29365144
[19]	TISCHKOWITZ M, HUANG S D, BANERJEE S, et al. Small-cell carcinoma of the ovary, hypercalcemic type-genetics, new treatment targets, and current management guidelines[J]. Clin Cancer Res, 2020, 26(15): 3908-3917. doi: 10.1158/1078-0432.CCR-19-3797 pmid: 32156746
[20]	ZHANG F F, WANG W J, LONG Y, et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response[J]. Cancer Commun (Lond), 2018, 38(1): 60.
[21]	BERCHUCK A, WITKOWSKI L, HASSELBLATT M, et al. Prophylactic oophorectomy for hereditary small cell carcinoma of the ovary, hypercalcemic type[J]. Gynecol Oncol Rep, 2015, 12: 20-22.

1例SMARCA4胚系变异卵巢高钙血症型小细胞癌的综合治疗和遗传咨询

Comprehensive therapy and genetic counseling for one patient with SMARCA4 germline-mutated small cell carcinoma, the ovary of hypercalcemic type

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 21

相关文章 6

编辑推荐

Metrics

本文评价

[1]	中国抗癌协会妇科肿瘤专业委员会, 中国抗癌协会肿瘤多学科诊疗（MDT）专业委员会, 中国医师协会肿瘤多学科诊疗专业委员会. 妇科恶性肿瘤多学科诊疗中国专家共识（2022年版）[J]. 中国癌症杂志, 2022, 32(8): 747-756.
[2]	康茗贻, 郜意, 胥婧, 康玉, 徐丛剑. 单细胞RNA测序技术揭示卵巢高钙血症型小细胞癌复发病灶的细胞分子特征[J]. 中国癌症杂志, 2022, 32(11): 1065-1073.
[3]	任玉兰, 林　洁, 常　彬, 王华英 . 57例原发女性生殖系统淋巴瘤临床特征分析[J]. 中国癌症杂志, 2020, 30(12): 1002-1007.
[4]	胡群超,俞晓立,郭小毛. 放疗在乳腺癌骨转移中的临床应用进展[J]. 中国癌症杂志, 2016, 26(4): 346-350.
[5]	蔡国响,孟献珂,蔡三军. 结直肠癌腹膜转移的多学科综合治疗[J]. 中国癌症杂志, 2015, 25(11): 890-894.
[6]	徐烨. 大肠癌的外科治疗[J]. 中国癌症杂志, 2013, 23(5): 389-398.